Abstract |
In this double-blind study to compare safety of 2 lipid formulations of amphotericin B, neutropenic patients with unresolved fever after 3 days of antibacterial therapy were randomized (1:1:1) to receive amphotericin B lipid complex (ABLC) at a dose of 5 mg/kg/d (n=78), liposomal amphotericin B (L Amph) at a dose of 3 mg/kg/d (n=85), or L Amph at a dose of 5 mg/kg/d (n=81). L Amph (3 mg/kg/d and 5 mg/kg/d) had lower rates of fever (23.5% and 19.8% vs. 57.7% on day 1; P<.001), chills/rigors (18.8% and 23.5% vs. 79.5% on day 1; P<.001), nephrotoxicity (14.1% and 14.8% vs. 42.3%; P<.01), and toxicity-related discontinuations of therapy (12.9% and 12.3% vs. 32.1%; P=.004). After day 1, infusional reactions were less frequent with ABLC, but chills/rigors were still higher (21.0% and 24.3% vs. 50.7%; P<.001). Therapeutic success was similar in all 3 groups.
|
Authors | J R Wingard, M H White, E Anaissie, J Raffalli, J Goodman, A Arrieta, L Amph/ABLC Collaborative Study Group |
Journal | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
(Clin Infect Dis)
Vol. 31
Issue 5
Pg. 1155-63
(Nov 2000)
ISSN: 1058-4838 [Print] United States |
PMID | 11073745
(Publication Type: Clinical Trial, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antifungal Agents
- Drug Carriers
- Liposomes
- Amphotericin B
|
Topics |
- Adolescent
- Adult
- Aged
- Aged, 80 and over
- Amphotericin B
(adverse effects, therapeutic use)
- Antifungal Agents
(adverse effects, therapeutic use)
- Child
- Child, Preschool
- Chills
(chemically induced)
- Double-Blind Method
- Drug Carriers
- Female
- Fever
(chemically induced)
- Humans
- Infusions, Intravenous
- Liposomes
- Male
- Middle Aged
- Mycoses
(prevention & control)
- Nausea
(chemically induced)
- Neutropenia
(drug therapy, mortality)
- Survival Rate
- Vomiting
(chemically induced)
|